[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

May 2024 | 137 pages | ID: MA0E2C08A781EN
IMARC Group

US$ 6,499.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The 7 major menorrhagia markets reached a value of US$ 970 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,380 Million by 2034, exhibiting a growth rate (CAGR) of 3.26% during 2024-2034.

The menorrhagia market has been comprehensively analyzed in IMARC's new report titled "Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Menorrhagia is a medical term used to describe prolonged or abnormally heavy menstrual bleeding in women. It refers to menstrual periods that involve excessive blood loss, typically exceeding 80 milliliters or lasting longer than seven days. This condition can be distressing and may interfere with a woman's daily activities and quality of life. The common symptoms associated with the ailment include abdominal pain, passing blood clots that are the size of a quarter or bigger, fatigue, weakness, shortness of breath, pale skin, intense cramping, etc. To diagnose menorrhagia, a healthcare provider may review the woman's medical history, conduct a physical examination, and suggest additional tests, such as blood workups, to check for anemia or hormonal imbalances. A transvaginal ultrasound, which involves inserting a probe into the vagina to obtain pictures of the uterus and ovaries to help in identifying structural abnormalities, is also utilized among patients. The doctor may further recommend several diagnostic procedures, including magnetic resonance imaging, hysteroscopy, endometrial biopsy, etc., to rule out other possible causes and validate a diagnosis.

The rising incidences of hormonal imbalances, particularly between estrogen and progesterone, that can disrupt the normal menstrual cycle and lead to heavy bleeding are primarily driving the menorrhagia market. In addition to this, the increasing prevalence of various associated risk factors, such as the use of intrauterine devices, blood clotting disorders, endometrial polyps, etc., is also bolstering the market growth. Furthermore, the widespread adoption of nonsteroidal anti-inflammatory drugs, including ibuprofen and naproxen sodium, to reduce menstrual bleeding and alleviate pain is acting as another significant growth-inducing factor. Apart from this, the escalating application of minimally invasive endometrial ablation therapy for women who prefer non-hormonal treatment, owing to its numerous advantages, such as rapid recovery time, cost-effectiveness, and improved quality of life, is also creating a positive outlook for the market. Additionally, the emerging popularity of uterine artery embolization techniques for treating this disease condition, since they block the blood flow to the uterus by injecting tiny particles into the uterine arteries, leading to symptom relief, is expected to drive the menorrhagia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the menorrhagia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for menorrhagia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the menorrhagia market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the menorrhagia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the menorrhagia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current menorrhagia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the menorrhagia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the menorrhagia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the menorrhagia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of menorrhagia across the seven major markets?
What is the number of prevalent cases (2018-2034) of menorrhagia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of menorrhagia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with menorrhagia across the seven major markets?
What is the size of the menorrhagia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of menorrhagia?
What will be the growth rate of patients across the seven major markets?

Menorrhagia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for menorrhagia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the menorrhagia market?
What are the key regulatory events related to the menorrhagia market?
What is the structure of clinical trial landscape by status related to the menorrhagia market?
What is the structure of clinical trial landscape by phase related to the menorrhagia market?
What is the structure of clinical trial landscape by route of administration related to the menorrhagia market?
1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MENORRHAGIA - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 MENORRHAGIA - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 MENORRHAGIA - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
  7.2.1 Epidemiology Scenario (2018-2023)
  7.2.2 Epidemiology Forecast (2024-2034)
  7.2.3 Epidemiology by Age (?2018-2034?)
  7.2.4 Epidemiology by Gender (?2018-2034?)
  7.2.5 Diagnosed Cases (?2018-2034?)
  7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
  7.3.1 Epidemiology Scenario (2018-2023)
  7.3.2 Epidemiology Forecast (2024-2034)
  7.3.3 Epidemiology by Age (?2018-2034?)
  7.3.4 Epidemiology by Gender (?2018-2034?)
  7.3.5 Diagnosed Cases (?2018-2034?)
  7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
  7.4.1 Epidemiology Scenario (2018-2023)
  7.4.2 Epidemiology Forecast (2024-2034)
  7.4.3 Epidemiology by Age (?2018-2034?)
  7.4.4 Epidemiology by Gender (?2018-2034?)
  7.4.5 Diagnosed Cases (?2018-2034?)
  7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
  7.5.1 Epidemiology Scenario (2018-2023)
  7.5.2 Epidemiology Forecast (2024-2034)
  7.5.3 Epidemiology by Age (?2018-2034?)
  7.5.4 Epidemiology by Gender (?2018-2034?)
  7.5.5 Diagnosed Cases (?2018-2034?)
  7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
  7.6.1 Epidemiology Scenario (2018-2023)
  7.6.2 Epidemiology Forecast (2024-2034)
  7.6.3 Epidemiology by Age (?2018-2034?)
  7.6.4 Epidemiology by Gender (?2018-2034?)
  7.6.5 Diagnosed Cases (?2018-2034?)
  7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
  7.7.1 Epidemiology Scenario (2018-2023)
  7.7.2 Epidemiology Forecast (2024-2034)
  7.7.3 Epidemiology by Age (?2018-2034?)
  7.7.4 Epidemiology by Gender (?2018-2034?)
  7.7.5 Diagnosed Cases (?2018-2034?)
  7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
  7.8.1 Epidemiology Scenario (2018-2023)
  7.8.2 Epidemiology Forecast (2024-2034)
  7.8.3 Epidemiology by Age (?2018-2034?)
  7.8.4 Epidemiology by Gender (?2018-2034?)
  7.8.5 Diagnosed Cases (?2018-2034?)
  7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
  7.9.1 Epidemiology Scenario (2018-2023)
  7.9.2 Epidemiology Forecast (2024-2034)
  7.9.3 Epidemiology by Age (?2018-2034?)
  7.9.4 Epidemiology by Gender (?2018-2034?)
  7.9.5 Diagnosed Cases (?2018-2034?)
  7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 MENORRHAGIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 MENORRHAGIA - UNMET NEEDS

10 MENORRHAGIA - KEY ENDPOINTS OF TREATMENT

11 MENORRHAGIA - MARKETED PRODUCTS

11.1 List of Menorrhagia Marketed Drugs Across the Top 7 Markets
  11.1.1 Lysteda (Tranexamic acid controlled release) - Amring Pharmaceuticals
    11.1.1.1 Drug Overview
    11.1.1.2 Mechanism of Action
    11.1.1.3 Regulatory Status
    11.1.1.4 Clinical Trial Results
    11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 MENORRHAGIA - PIPELINE DRUGS

12.1 List of Menorrhagia Pipeline Drugs Across the Top 7 Markets
  12.1.1 Drug Name – Company Name
    12.1.1.1 Drug Overview
    12.1.1.2 Mechanism of Action
    12.1.1.3 Clinical Trial Results
    12.1.1.4 Safety and Efficacy
    12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.

13. MENORRHAGIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. MENORRHAGIA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 MENORRHAGIA - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
  15.2.1 Menorrhagia - Market Size
    15.2.1.1 Market Size (2018-2023)
    15.2.1.2 Market Forecast (2024-2034)
  15.2.2 Menorrhagia - Market Size by Therapies
    15.2.2.1 Market Size by Therapies (2018-2023)
    15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
  15.3.1 Menorrhagia - Market Size
    15.3.1.1 Market Size (2018-2023)
    15.3.1.2 Market Forecast (2024-2034)
  15.3.2 Menorrhagia - Market Size by Therapies
    15.3.2.1 Market Size by Therapies (2018-2023)
    15.3.2.2 Market Forecast by Therapies (2024-2034)
  15.3.3 Menorrhagia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
  15.4.1 Menorrhagia - Market Size
    15.4.1.1 Market Size (2018-2023)
    15.4.1.2 Market Forecast (2024-2034)
  15.4.2 Menorrhagia - Market Size by Therapies
    15.4.2.1 Market Size by Therapies (2018-2023)
    15.4.2.2 Market Forecast by Therapies (2024-2034)
  15.4.3 Menorrhagia - Access and Reimbursement Overview
15.5 Market Scenario - France
  15.5.1 Menorrhagia - Market Size
    15.5.1.1 Market Size (2018-2023)
    15.5.1.2 Market Forecast (2024-2034)
  15.5.2 Menorrhagia - Market Size by Therapies
    15.5.2.1 Market Size by Therapies (2018-2023)
    15.5.2.2 Market Forecast by Therapies (2024-2034)
  15.5.3 Menorrhagia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
  15.6.1 Menorrhagia - Market Size
    15.6.1.1 Market Size (2018-2023)
    15.6.1.2 Market Forecast (2024-2034)
  15.6.2 Menorrhagia - Market Size by Therapies
    15.6.2.1 Market Size by Therapies (2018-2023)
    15.6.2.2 Market Forecast by Therapies (2024-2034)
  15.6.3 Menorrhagia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
  15.7.1 Menorrhagia - Market Size
    15.7.1.1 Market Size (2018-2023)
    15.7.1.2 Market Forecast (2024-2034)
  15.7.2 Menorrhagia - Market Size by Therapies
    15.7.2.1 Market Size by Therapies (2018-2023)
    15.7.2.2 Market Forecast by Therapies (2024-2034)
  15.7.3 Menorrhagia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
  15.8.1 Menorrhagia - Market Size
    15.8.1.1 Market Size (2018-2023)
    15.8.1.2 Market Forecast (2024-2034)
  15.8.2 Menorrhagia - Market Size by Therapies
    15.8.2.1 Market Size by Therapies (2018-2023)
    15.8.2.2 Market Forecast by Therapies (2024-2034)
  15.8.3 Menorrhagia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
  15.9.1 Menorrhagia - Market Size
    15.9.1.1 Market Size (2018-2023)
    15.9.1.2 Market Forecast (2024-2034)
  15.9.2 Menorrhagia - Market Size by Therapies
    15.9.2.1 Market Size by Therapies (2018-2023)
    15.9.2.2 Market Forecast by Therapies (2024-2034)
  15.9.3 Menorrhagia - Access and Reimbursement Overview

16 MENORRHAGIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 MENORRHAGIA MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 MENORRHAGIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX


More Publications